Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Safety, pharmacokinetics and efficacy of SCT200, an anti-EGFR monoclonal antibody in patients with wild-type KRAS/NRAS/BRAF metastatic colorectal cancer: a phase I dose-escalation and dose-expansion study

Abstract Background An over-expression of the epidermal growth factor receptor (EGFR) has been observed in colorectal cancer and is associated with aggressive disease and poor prognosis. SCT200 is a newly developed recombinant, fully humanized, anti-EGFR monoclonal antibody. This study aimed to eval...

Full description

Bibliographic Details
Main Authors: Wen Zhang, Xiaohong Han, Lin Yang, Yuanyuan Song, Liangzhi Xie, Wenlin Gai, Yan Wang, Yuankai Shi
Format: Article
Language:English
Published: BMC 2022-10-01
Series:BMC Cancer
Subjects:
Monoclonal antibodies
Colorectal cancer
Epidermal Growth Factor Receptor
SCT200
Online Access:https://doi.org/10.1186/s12885-022-10147-9

Internet

https://doi.org/10.1186/s12885-022-10147-9

Similar Items